Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis.
U.S. FDA grants Breakthrough Therapy Designation for Roche’s investigational medicine ocrelizumab in primary progressive multiple sclerosis
Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.
Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D.
Biogen Idec and Genentech Announce Restructuring of anti-CD20 Collaboration Agreement
Episode 51 with Dr. Luke Lairson on discovery of small molecules to induce remyelination
Histologie de la sclerose en plaques
Unusual association of Arnold-Chiari malformation and vitamin B12 deficiency.
FDA Warns About CCSVI Treatment
A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Episode 71 with Dr. Brian Weinshenker on innovative clinical trials for NMO
MS Research Roundup: January 9, 2014
MS Patient, Ph.D.: Setting the Right Expectations for Recovery
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
MS Research Roundup: April 23, 2014
Multiple sclerosis and pregnancy: experience from a nationwide database in Germany.
New therapies in the management of rheumatoid arthritis.
A Study of Efficacy and Safety of Ocrelizumab in Patients with Relapse-Remitting Multiple Sclerosis
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Improper Inducements
Safety study of BIIB033 in subjects with multiple sclerosis
Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)
MS Research Roundup: February 5, 2014
Epitope spreading as an early pathogenic event in pediatric multiple sclerosis.

Pages